Aptamers and diagnostic methods for detecting the EGF receptor
The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3′ cap. In some embodiments, the 3′ cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5′-end of the aptamer and the moiety is attached the 5′ end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.
1. A method for determining the amount of free Epidermal Growth Factor Receptor (EGFR) in a sample comprising:
(a) contacting a sample comprising EGFR with an aptamer that specifically binds to free EGFR under conditions that allow binding of the aptamer to the free EGFR in the sample to form an aptamer-EGFR complex, wherein the free EGFR is EGFR that is not bound to a therapeutic molecule if present in the sample, and wherein the aptamer comprises the structure defined by SEQ ID NO: 55;
(b) detecting the amount of the free EGFR bound by the aptamer; and
(c) determining the amount of free EGFR in the sample based on the amount of the free EGFR bound by the aptamer.
2. The method of claim 1 , wherein the aptamer comprises the structure defined by a sequence selected from the group comprising SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.
3. The method of claim 1 , wherein the aptamer comprises a first binding pair member and is immobilized on a first solid support via a second binding pair member that specifically binds to the first binding pair member.
4. The method of claim 3 , wherein the sample is contacted with the aptamer prior to immobilization on the first solid support.
5. The method of claim 3 , wherein the sample is contacted with the aptamer after immobilization on the first solid support.
6. The method of claim 3 , wherein the amount of free EGFR is determined by determining the amount of EGFR immobilized on the first solid support.
7. The method of claim 6 , wherein the amount of EGFR immobilized on the first solid support is determined using an antibody that specifically binds to the immobilized EGFR.
8. The method of claim 3 , said method further comprising:
(i) attaching a third binding pair member to the EGFR;
(ii) releasing the aptamer-EGFR complex from the solid support;
(iii) immobilizing the aptamer-EGFR complex on a second solid support via a fourth binding pair member that specifically binds to the third binding pair member; and
(iv) determining the amount of EGFR immobilized to the second solid support.
9. The method of claim 8 , wherein the amount of EGFR immobilized on the second solid support is determined using an antibody that specifically binds to EGFR.
10. The method of claim 8 , said method further comprises labeling the EGFR with a detectable label either before or after immobilization on the second solid support.
11. The method of claim 10 , wherein the aptamer further comprises a detectable label.
12. The method of claim 8 , wherein the amount of EGFR immobilized on the solid support is determined using flow cytometry.
13. The method of claim 8 , wherein the amount of EGFR immobilized on the second solid support is determined by releasing the aptamer from the aptamer-EGFR complex and determining the amount of the released aptamer.
14. The method of claim 13 , wherein the amount of the released aptamer is determined by amplification of the aptamer.
15. The method of claim 1 , further comprising detecting the total amount of EGFR in the sample using an enzyme-linked immunosorbent assay.
16. The method of claim 1 , wherein the sample is a serum sample.
17. The method of claim 1 , wherein the sample is from a human patient.
18. The method of claim 17 , wherein the patient has cancer.
19. The method of claim 17 , wherein the patient is receiving an anti-EGFR receptor therapy.
20. The method of claim 17 , wherein the patient is receiving cetuximab or panitumumab.
21. The method of claim 1 , wherein the therapeutic molecule is an anti-EGFR receptor antibody.
22. The method of claim 21 , wherein the anti-EGFR receptor antibody is cetuximab or panitumumab.
23. The method of claim 1 , wherein X of SEQ ID NO: 55 is G, C, or A; Y of SEQ ID NO: 55 is G or A and/or each N of SEQ ID NO: 55 is, independently, a 5-position modified 2′-deoxyuridine.
24. The method of claim 1 , wherein each N of SEQ ID NO: 55 is, independently, selected from a 5-benzylaminocarbonyl-2′-deoxyuridine, 5-(N-benzylcarboxyamide)-2′-deoxyuridine, 5-(N-isobutylcarboxyamide)-2′-deoxyuridine, 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine, 5-(N-[1-(3-trimethylamonium) propyl]carboxyamide)-2′-deoxyuridine chloride, 5-(N-naphthylmethylcarboxamide)-2′-deoxyuridine and a 5-(N-[1-(2,3-dihydroxypropyl)]carboxyamide)-2′-deoxyuridine.